🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "huge turning point" in the fight against drug-resistant strains of the infection, according to health experts.

An International Health Concern

Cases of gonorrhoea are on the rise worldwide, with figures suggesting more than 82 million new cases per year. Especially elevated rates are observed in the African continent and countries within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune development in the face of rising global incidence, escalating drug resistance and the extremely scarce available drugs presently on offer.”

Medical experts are deeply concerned about the surge in treatment-resistant strains. The global health body has listed it as a "priority pathogen". Ongoing monitoring revealed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Treatment Options Secure Authorization

Zoliflodacin, also known as a brand name, was approved by the US FDA in December for combating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Experts hope that specific application of this new drug will help slow the spread of drug resistance.

Another new antibiotic, developed by the pharmaceutical company GSK, gained clearance in the same week. This medication, which is additionally indicated for urinary tract infections, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for medication research. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to develop it.

“This authorization represents a major breakthrough in the management of superbug gonorrhoea, which previously has been evolving faster than medical innovation.”

Testing Outcomes and Global Access

As per results released by a prominent scientific publication, zoliflodacin eradicated over nine in ten of uncomplicated infections. This puts it on an equal footing with the current standard treatment, which involves an injection and a pill. The research involved over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the rights to register and commercialise the drug in many regions with limited resources.

Clinicians treating patients have expressed optimism. The availability of a easy-to-administer therapy of this kind is seen as a "critical tool" for managing the epidemic. This is deemed essential to reduce the burden of the disease for individuals and to stop the proliferation of highly drug-resistant gonorrhoea globally.